iRhythm Technologies

Zio AT transmits real-time AFib detection alerts to the patient’s iPhone or Android within 30 minutes of an episode via Bluetooth, enabling anticoagulation conversations between patient and physician before the 14-day wear ends. The full retrospective report analyses 100% of all cardiac beats over the monitoring period — unlike Holter monitors that analyse a 24-48 hour sample — yielding dramatically higher diagnostic yield for paroxysmal arrhythmias. Dual AI engine combines a CNN rhythm classifier with rule-based adjudication to achieve 99.6% sensitivity for AFib, validated against cardiologist annotation on 90,000+ patient recordings. Over-the-counter clearance (FDA De Novo 2023) allows pharmacies to dispense to patients without a prior physician encounter in some US states.